AtlasClear Holdings announced the signing of its ninth correspondent broker-dealer agreement through its subsidiary AtlasClearing, contributing to an 85% revenue increase to $20.1 million in fiscal 2026. This growth occurred before significant revenue from the new correspondents, highlighting strong underlying business momentum. The company also improved its financial health with positive stockholders' equity and doubled cash reserves. AtlasClear plans to continue expanding its clearing network and converting new agreements into active revenue streams.
AtlasClear's recent expansion to its ninth correspondent broker-dealer agreement comes alongside strong sector activity. For readers following Financials, here is Pluang's market snapshot as of Nov 12, 2026 06:01 WIB: 94 of 142 priced US Financials stocks rose today. Notable movers include LMND at USD 40.60 with a +3.36% change and VIRT at USD 59.62 with a +3.24% change.
Ashland Inc.'s board of directors declared a quarterly cash dividend of $0.42 per share, payable on December 15, 2026, to shareholders of record as of December 1, 2026. This dividend reflects the company's ongoing commitment to returning value to sha...
AeroVironment secured a $405 million international order for its LOCUST X3 high-energy laser weapon systems, enhancing counter-drone defense capabilities in the Middle East amid rising regional security threats. Following the announcement, AeroVironm...
Vestas Wind Systems reported Q3 2026 earnings per share of $0.13 and revenue of $6.34 billion, both below analyst expectations. The company's profit was impacted by weak sales volume and a broken turbine blade. Following the earnings miss, Vestas' sh...
The global beverage market is projected to grow from $2.03 trillion in 2026 to $2.78 trillion by 2032, at a CAGR of 5.35%. Growth is fueled by rising demand for nonalcoholic and functional beverages, convenience packaging, and premium products for sp...
DelveInsight's 2026 report reveals more than 200 GLP-1 receptor agonists and incretin-based therapies are in development by over 180 companies, targeting conditions like type 2 diabetes, obesity, and related metabolic disorders. Key players such as E...
